ES2725150T3 - Biomarcador - Google Patents
Biomarcador Download PDFInfo
- Publication number
- ES2725150T3 ES2725150T3 ES09805934T ES09805934T ES2725150T3 ES 2725150 T3 ES2725150 T3 ES 2725150T3 ES 09805934 T ES09805934 T ES 09805934T ES 09805934 T ES09805934 T ES 09805934T ES 2725150 T3 ES2725150 T3 ES 2725150T3
- Authority
- ES
- Spain
- Prior art keywords
- acid sequence
- seq
- cancer
- biomarker
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 45
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 47
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 44
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 44
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 25
- 210000002700 urine Anatomy 0.000 claims abstract description 22
- 239000012634 fragment Substances 0.000 claims abstract description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 15
- 150000001413 amino acids Chemical class 0.000 claims abstract description 15
- 210000005068 bladder tissue Anatomy 0.000 claims abstract description 9
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 7
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 40
- 230000000295 complement effect Effects 0.000 claims description 3
- 108700005856 engrailed 2 Proteins 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000020816 lung neoplasm Diseases 0.000 description 14
- 201000005202 lung cancer Diseases 0.000 description 13
- 239000000523 sample Substances 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000013060 biological fluid Substances 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 4
- 101150118342 EN2 gene Proteins 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000011330 nucleic acid test Methods 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 239000000107 tumor biomarker Substances 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0823445.2A GB0823445D0 (en) | 2008-12-23 | 2008-12-23 | Biomarker |
| PCT/GB2009/002926 WO2010073001A1 (en) | 2008-12-23 | 2009-12-21 | Biomarker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2725150T3 true ES2725150T3 (es) | 2019-09-19 |
Family
ID=40344114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09805934T Active ES2725150T3 (es) | 2008-12-23 | 2009-12-21 | Biomarcador |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9624548B2 (enExample) |
| EP (1) | EP2382327B1 (enExample) |
| JP (1) | JP5947040B2 (enExample) |
| CN (1) | CN102301006B (enExample) |
| AU (1) | AU2009332712B2 (enExample) |
| BR (1) | BRPI0923525A2 (enExample) |
| CA (1) | CA2747760C (enExample) |
| ES (1) | ES2725150T3 (enExample) |
| GB (1) | GB0823445D0 (enExample) |
| IL (1) | IL213510A (enExample) |
| MX (1) | MX343251B (enExample) |
| NZ (1) | NZ593392A (enExample) |
| RU (1) | RU2573925C2 (enExample) |
| WO (1) | WO2010073001A1 (enExample) |
| ZA (1) | ZA201105184B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| EP3508498A1 (en) | 2011-01-19 | 2019-07-10 | Cantargia AB | Novel agents and uses thereof |
| US11371941B2 (en) * | 2016-07-04 | 2022-06-28 | Celltool Gmbh | Device and method for the determination of transfection |
| KR101777085B1 (ko) * | 2017-02-23 | 2017-09-11 | 주식회사 성균바이오텍 | En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물 |
| KR101923199B1 (ko) | 2018-04-25 | 2018-11-28 | 주식회사 무진메디 | 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물 |
| EP4043583A4 (en) | 2019-10-02 | 2023-11-08 | Kyushu University, National University Corporation | Biomarker, method, kit and array for predicting therapeutic effects of bcg intravesical infusion therapy in treating bladder cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2469089A1 (en) | 2003-07-08 | 2005-01-08 | Institut De Recherches Cliniques De Montreal | En-2 gene, disgnostic and therapeutic uses thereof |
| EP2295601A1 (en) * | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| GB0625321D0 (en) * | 2006-12-19 | 2007-01-24 | Univ Surrey | Cancer biomarker |
| ES2384071T3 (es) * | 2007-01-19 | 2012-06-29 | Epigenomics Ag | Métodos y ácidos nucleicos para análisis de trastornos proliferativos celulares |
| JP5694776B2 (ja) | 2007-12-11 | 2015-04-01 | エピゲノミクス アーゲー | 細胞増殖性障害の解析のための方法及び核酸 |
-
2008
- 2008-12-23 GB GBGB0823445.2A patent/GB0823445D0/en not_active Ceased
-
2009
- 2009-12-21 EP EP09805934.8A patent/EP2382327B1/en not_active Not-in-force
- 2009-12-21 MX MX2011006773A patent/MX343251B/es active IP Right Grant
- 2009-12-21 BR BRPI0923525-6A patent/BRPI0923525A2/pt not_active Application Discontinuation
- 2009-12-21 JP JP2011541583A patent/JP5947040B2/ja not_active Expired - Fee Related
- 2009-12-21 ES ES09805934T patent/ES2725150T3/es active Active
- 2009-12-21 NZ NZ593392A patent/NZ593392A/xx not_active IP Right Cessation
- 2009-12-21 WO PCT/GB2009/002926 patent/WO2010073001A1/en not_active Ceased
- 2009-12-21 AU AU2009332712A patent/AU2009332712B2/en not_active Ceased
- 2009-12-21 CN CN200980155785.7A patent/CN102301006B/zh not_active Expired - Fee Related
- 2009-12-21 US US13/141,787 patent/US9624548B2/en active Active
- 2009-12-21 CA CA2747760A patent/CA2747760C/en active Active
- 2009-12-21 RU RU2011130795/10A patent/RU2573925C2/ru not_active IP Right Cessation
-
2011
- 2011-06-13 IL IL213510A patent/IL213510A/en active IP Right Grant
- 2011-07-14 ZA ZA2011/05184A patent/ZA201105184B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2747760A1 (en) | 2010-07-01 |
| MX2011006773A (es) | 2011-08-03 |
| US20120020888A1 (en) | 2012-01-26 |
| NZ593392A (en) | 2013-05-31 |
| CA2747760C (en) | 2020-01-21 |
| IL213510A0 (en) | 2011-07-31 |
| CN102301006B (zh) | 2015-07-15 |
| AU2009332712B2 (en) | 2015-05-28 |
| ZA201105184B (en) | 2012-02-29 |
| US9624548B2 (en) | 2017-04-18 |
| AU2009332712A1 (en) | 2011-07-07 |
| GB0823445D0 (en) | 2009-01-28 |
| JP5947040B2 (ja) | 2016-07-06 |
| JP2012513584A (ja) | 2012-06-14 |
| WO2010073001A1 (en) | 2010-07-01 |
| EP2382327B1 (en) | 2019-02-13 |
| MX343251B (es) | 2016-10-31 |
| CN102301006A (zh) | 2011-12-28 |
| RU2573925C2 (ru) | 2016-01-27 |
| BRPI0923525A2 (pt) | 2020-08-11 |
| IL213510A (en) | 2016-04-21 |
| EP2382327A1 (en) | 2011-11-02 |
| RU2011130795A (ru) | 2013-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2445185T3 (es) | Biomarcadores de cáncer | |
| ES2725150T3 (es) | Biomarcador | |
| CN106701964A (zh) | 血清外泌体miRNA生物标志物及用于胃癌早期诊断的试剂盒 | |
| JP6192122B2 (ja) | 結腸直腸癌診断および予測のためのバイオマーカー | |
| KR102061891B1 (ko) | 폐암 질환의 진단용 마커 | |
| CN113774140A (zh) | 一种预测结直肠癌对奥沙利铂治疗敏感性的产品 | |
| KR20230160425A (ko) | 췌장암의 진단용 조성물 | |
| KR102499664B1 (ko) | 암의 진단용 조성물 | |
| KR102216386B1 (ko) | 암의 진단용 조성물 | |
| EP3701049B1 (en) | Diagnosis and/or prognosis of her2-dependent cancer using moesin as a biomarker | |
| KR20220126661A (ko) | 췌장암의 진단용 조성물 | |
| CN113817829A (zh) | 生物标志物在制备预测结直肠癌对奥沙利铂治疗敏感性的产品中的用途 | |
| CN113846165A (zh) | 生物标志物在预测结直肠癌对奥沙利铂治疗敏感性中的应用 | |
| US20030198961A1 (en) | Determining cancer aggressiveness | |
| WO2011012763A2 (es) | Método y kit para el pronóstico de linfoma de células del manto | |
| KR102499678B1 (ko) | 암의 진단용 조성물 | |
| KR102280672B1 (ko) | 암의 진단용 조성물 | |
| KR102325742B1 (ko) | 암의 진단용 조성물 | |
| ES2343996B1 (es) | Metodo para la subclasificacion de tumores. | |
| KR102280360B1 (ko) | 암의 진단용 조성물 | |
| KR102325731B1 (ko) | 암의 진단용 조성물 | |
| WO2016060382A1 (ko) | 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법 | |
| KR20210040921A (ko) | 신장암 환자의 치료 전략 결정 및 예후 진단용 재발 특이적 마커 | |
| JP4677565B2 (ja) | 癌に特異的な遺伝子及びそれを用いた診断キット | |
| CN113817830A (zh) | 用于预测结直肠癌对奥沙利铂治疗敏感性的方法 |